Medicinal Products

BETANOL 0.6%

Generic drug of the therapeutic class: Ophthalmology
active ingredients: Methipranolol
laboratory: Europhta

eyewash
Bottle of 3 ml
All forms

Indication

- Intraocular hypertonia.
- Chronic open angle glaucoma.

Dosage BETANOL 0.6% Eye drops 3 ml bottle

Local way.
IN EYE INSTILLATION.
The dosage is one drop of BETANOL 0.6 PERCENT, to be instilled in the sick eye, twice a day.
- It is recommended to start treatment with BETANOL 0.1 PERCENT eye drops.
- The 0.6% dosage should be reserved for patients who have not responded to 0.1% or 0.3% dosages.
In a number of cases, the daily administration of a single drop of metipranolol in eye drops may be sufficient, especially when the intraocular pressure has been maintained at satisfactory levels.
- The ophthalmologist may, if he deems it necessary, associate metipranolol with eye drops with one or more other antiglaucomatous treatments (locally and / or generally).
- However, the combination of two beta-blocking eye drops is not recommended (see precautions for use).
- The other eye drops should be administered at least 15 minutes before BETANOL.
However, the normalization of ocular pressure by the eye drops sometimes requires a few weeks, so the evaluation of the treatment should include a measurement of intraocular pressure after a treatment period of about 4 weeks.
Substitution of previous treatment:
- When the eye drops BETANOL must take over another antiglaucoma eye drops, this eye drops should be stopped at the end of a full day of treatment, and BETANOL should be administered the next day at a rate of 0, 6% in the sick eye, twice a day.
- If BETANOL eye drops are to be substituted for several antiglaucomatous agents, deletions should be made for only one drug at a time.
- In the case of substitution of eye drops with BETANOL eye drops, an examination of the refraction may be necessary when the effects of miotics have disappeared.
- The medical prescription will be accompanied by the control of intraocular pressure, especially during the initiation of treatment.

Against indications

The contraindications to systemically administered beta-blockers should be borne in mind, although the systemic effects of beta-blockers are only exceptionally observed after eye instillation .
CONTRAINDICATED:
- hypersensitivity to any of the components of the drug,
- asthma or chronic obstructive pulmonary disease,
- heart failure not controlled by treatment,
- cardiogenic shock,
- non-paired second and third degree atrioventricular blocks, Prinzmetal's angina,
- sinus disease (including sinoatrial block),
- bradycardia (<45-50 contractions per minute),
- Raynaud's disease and circulatory disorders,
- untreated pheochromocytoma,
- hypotension,
- association with floctafenine (see interactions),
- association with sultopride (see interactions).
NOT RECOMMENDED :
- This drug should not usually be associated with amiodarone (see interactions).
- The combination of two beta-blocking eye drops is not recommended.
- Use in children: this eye drops has not been the subject of clinical studies in premature infants, newborns and children. The use of this eye drops is not recommended in these patients.
- Breast-feeding: Beta-blockers are excreted in the milk. The risk of hypoglycaemia and bradycardia has not been evaluated: therefore, as a precaution, breastfeeding is not recommended during the course of treatment.

Betanol side effects

EYES :
As with all beta-blocker eye drops, it can be observed:
- a decrease of the lacrimal secretion (dry eye);
- symptoms of eye irritation: slight burning or stinging sensation at the beginning of treatment;
conjunctival hyperemia, conjunctivitis, blepharitis, keratitis, corneal hypoesthesia;
- visual disturbances including changes in refraction (sometimes due to cessation of treatment by miotics), diplopia, ptosis;
- choroidal detachment after surgical treatment of glaucoma (see warnings and precautions for use).
GENERAL
The side effects of systemically administered beta-blockers should be borne in mind, although they are only exceptionally observed after ocular instillation.
ON THE CLINICAL PLAN:
- The most frequently reported:
. asthenia,
. cooling of the ends,
. bradycardia, severe if any,
. insomnia, nightmares or depression,
. digestive disorders (gastralgia, nausea, vomiting, diarrhea).
- Much more rarely:
. slowing of atrioventricular conduction or intensification of an existing atrioventricular block,
. heart failure,
. blood pressure drop,
. bronchospasm,
. hypoglycemia,
. Raynaud's syndrome,
. worsening of existing intermittent claudication,
. skin manifestations including urticaria, angioedema (angioedema), rash, psoriasiform rash (see warnings and precautions for use).
ON THE BIOLOGICAL PLAN:
In rare cases, it has been possible to observe the appearance of antinuclear antibodies which only exceptionally accompany clinical manifestations such as lupus syndrome and cede at the end of treatment.

Popular Posts

Category Medicinal Products, Next Article